Compare VRME & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRME | INDP |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | United States | United States |
| Employees | 30 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0M | 5.2M |
| IPO Year | N/A | 2021 |
| Metric | VRME | INDP |
|---|---|---|
| Price | $0.65 | $1.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | ★ 62.5K | 45.6K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.85 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.59 | $0.27 |
| 52 Week High | $1.51 | $13.24 |
| Indicator | VRME | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 39.08 | 49.75 |
| Support Level | $0.64 | $1.64 |
| Resistance Level | $0.93 | $2.08 |
| Average True Range (ATR) | 0.05 | 0.21 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 27.28 | 80.37 |
VerifyMe Inc is a logistics company that specializes in time and temperature-sensitive products, as well as providing brand protection and enhancement solutions. The company operates through two reportable business segments: Precision Logistics offers a value-added service provider for time and temperature-sensitive parcel management. Using a proprietary IT platform, it provides real-time information and analysis to mitigate supply chain flow interruption, delivering last-mile resolution for key markets, including the perishable healthcare and food industries; and the Authentication segment specializes in anti-counterfeit and brand protection. The Precision Logistics segment derives the majority of the revenue.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.